Centre for Cellular & Molecular Biology (CCMB) has joined hands with the Ghaziabad-based Indian Pharmacoepia Commission (IPC) to facilitate regulatory process for biosimilars and herbal drugs on Sunday.
Biosimilars are biological products functioning like drugs against diseases and are rapidly making a mark in the healthcare sector across the world.
CSIR-CCMB director Rakesh Mishra and IPC Secretary G.N. Singh signed the memorandum of understanding which will come into immediate effect. Dr. Mishra said it is an important collaboration considering that there is increased usage in therapeutic proteins and herbal drugs for various diseases.
The emergence of biopharmaceutical drugs as a preferred choice for therapy over the conventional pharma drugs requires concerted efforts by various sectors towards production, characterisation and validation of indigenously developed products, he said.
The institutions will be working together on documentation and characterisation of Indian herbal drugs — phytopharmaceuticals, towards significant usage and export. The director said scientific validation and characterisation of herbal drugs will bring authenticity to the drugs and credibility to the industry as well as to the traditional knowledge.
